Key Market Insights

Presently, more than 70+ industry players are engaged in the development of artificial intelligence in oncology- based software solutions in different regions of the globe; a relatively larger proportion of these players are small firms

The Artificial Intelligence in Oncology market is dominated by companies based in North America; of these majority were established post 2010. 52% of these provide AI in oncology- based software solutions to hospitals

It is worth highlighting that 26% of the players engaged in this domain are using both machine learning and deep learning technologies

The rising interest in this rapidly evolving domain can be validated by the partnerships inked in recent years; majority of the deals were signed for technology integration agreements.

Both established players and new entrants have forged several partnerships; 60% of the companies involved in technology integration agreements are mid- sized

In order to tap the lucrative opportunity, venture capital firms / strategic investors have actively supported the ongoing initiatives; over USD 5.9 billion has been invested across 99+ instances in the last 5 years

Over the past few years, there has been a steady increase in the patent activity within this domain, growing at a cumulative annualized growth rate of 31%

Approximately 2,770 patents have been filed within this domain; of which 1,608 patents have been filed in the US

The market opportunity associated with Artificial Intelligence in Oncology is anticipated to witness an annualized growth of over 54%, over the coming decade

Table of Contents

1. PREFACE

1.1. Overview

1.2. Scope of the Report

1.3. Market Segmentation

1.4. Research Methodology

1.5. Key Questions Answered

1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

2.1 Chapter Overview

3. INTRODUCTION

3.1. Chapter Overview

3.2. Overview of Artificial Intelligence (AI)

3.3. Type Of AI

3.4. Applications of AI

3.5. Key Challenges Associated with Use of AI in Healthcare Sector

3.6. Future Perspectives

4. MARKET OVERVIEW

4.1. Chapter Overview

4.2. AI in Oncology: Market Landscape of Software providers

4.2.1. Analysis by Year of Establishment

4.2.2. Analysis by Company Size

4.2.3. Analysis by Location of Headquarters (Region-wise)

4.2.4. Analysis by Location of Headquarters (Country-wise)

4.2.5. Analysis by Type of End-User

4.2.6. Analysis by Year of Establishment, Company size and Location of Headquarters

4.3. AI in Oncology: Market Landscape of Software Solutions

4.3.1. Analysis by Type of Service(s) Offered

4.3.2. Analysis by Type of AI Technology Used

4.3.3. Analysis by Type of Platform

4.3.4. Analysis by Type of Service(s) Offered and Type of End-User

4.3.5. Analysis by Type of Platform and Type of AI Technology Used

4.3.6. Analysis by Type of Service(s) Offered, Location of Headquarters and Type of AI Technology Used

5. COMPANY PROFILES

5.1. Chapter Overview

5.2. Roche Diagnostics

5.2.1. Company Overview

5.2.2. Financial Information

5.2.3. AI Focused Service Portfolio

5.2.4. Recent Developments and Future Outlook

5.3. IBM Watson Health

5.3.1. Company Overview

5.3.2. Financial Information

5.3.3. AI Focused Service Portfolio

5.3.4. Recent Developments and Future Outlook

5.4. CancerCenter.AI

5.4.1. Company Overview

5.4.2. AI Focused Service Portfolio

5.4.3. Recent Development and Future Outlooks

5.5. GE Healthcare

5.5.1. Company Overview

5.5.2. Financial Information

5.5.3. AI Focused Service Portfolio

5.5.4. Recent Development and Future Outlook

5.6. Concert AI

5.6.1. Company Overview

5.6.2. AI Focused Service Portfolio

5.6.3. Recent Developments and Future Outlook

5.7. Path AI

5.7.1. Company Overview

5.7.2. AI Focused Service portfolio

5.7.3. Recent Development and Future Outlook

5.8. Berg

5.8.1. Company Overview

5.8.2. AI Focused Service Portfolio

5.8.3. Recent Development and Future Outlook

5.9. Median Technologies

5.9.1. Company Overview

5.9.2. Financial Information

5.9.3. AI Focused Service Portfolio

5.9.4. Recent Development and Future Outlook

5.10. iCAD

5.10.1. Company Overview

5.10.2. Financial Information

5.10.3. AI Focused Service Portfolio

5.10.4. Recent Developments and Future Outlook

5.11. JLK Inspection

5.11.1. Company Overview

5.11.2. AI Focused Service Portfolio

5.11.3. Recent Development and Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview

6.2. Assumptions and Key Parameters

6.3. Methodology

6.4. AI in Oncology Software providers: Company Competitiveness

6.4.1. Company Competitiveness: Small Companies in North America (Peer Group I)

6.4.2. Company Competitiveness: Small Companies in Europe (Peer Group II)

6.4.3. Company Competitiveness: Small Companies in Asia Pacific (Peer Group III)

6.4.4. Company Competitiveness: Mid-sized companies in North America (Peer Group IV)

6.4.5. Company Competitiveness: Mid-sized companies in Europe (Peer Group V)

6.4.6. Company Competitiveness: Mid-sized companies in Asia Pacific (Peer Group VI)

6.4.7. Company Competitiveness: Large companies in North America and Europe (Peer Group VII)

7. PATENT ANALYSIS

7.1. Chapter Overview

7.2. Scope and Methodology

7.3. AI in Oncology: Patent Analysis

7.3.1. Analysis by Type of Patent

7.3.2. Analysis by Patent Publication Year

7.3.3. Analysis by Year-wise Trend of Filed Patent Applications and Granted Patents

7.3.4. Analysis by Geography

7.3.5. Analysis by Type of Industry

7.3.6. Analysis by Patent Age <